Clin2
NCT07597018Possibly a fitRecruiting

Comparing Blood Levels of Cagrilintide Versions in Adults With Overweight

ObesityOverweight

Part of Hormones & metabolism clinical trials.

This early-stage study tests different formulations of cagrilintide, a new medication, to see how the body absorbs and processes each version. Cagrilintide may help with weight management. Researchers will measure blood levels after you receive multiple doses.

Summary written for real people, not researchers, by Clin2.

Phase
Phase 1
Enrollment
234 people
Ages
18 years to 64 years
Study type
Interventional

Who can take part

  • Age 18–64 years old
  • BMI (body mass index) between 27.0–34.9 kg/m² — roughly overweight but not obese
  • Overweight primarily from excess body fat, not muscle or other causes
  • Generally healthy with normal heart function, blood pressure, and lab tests
  • Never participated in a prior study using amylin analogues (a similar class of medication)
  • Able to follow study instructions and attend all visits

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT07557953Recruiting· Phase 1
How cagrilintide affects hunger and eating in overweight adults

This early-stage study tests a new medication called cagrilintide to see how it influences appetite and food intake in adults with overweight or obesity. Researchers want to understand if this drug could help people feel fuller and eat less.

Berlin
NCT07745504Not yet recruiting· Phase 3
Comparing two versions of a new weight-loss medication

This study compares two different versions of an investigational weight-loss medication (cagrilintide) against a placebo to see which is more effective and safe for people with excess weight. Participation involves receiving injections and regular check-ins to monitor your progress.

Conyers, Georgia
NCT07607587Recruiting· Phase 1
Testing a new weight-loss drug for people who couldn't tolerate GLP-1 shots

This study tests a new injectable medication called cagrilintide for people with obesity who had to stop GLP-1 drugs (like Ozempic or Wegovy) because of stomach problems. The goal is to see if cagrilintide causes fewer stomach side effects while still helping with weight.

Walnut Creek, California
NCT07253285Recruiting· Phase 3
Study on cagrilintide and CagriSema for kids with excess weight

This trial tests two new medicines (cagrilintide and CagriSema) to see if they help children and teens lose weight. It's for young people who have tried lifestyle changes without enough success.

Escondido, California
NCT07527195Recruiting· Phase 1
Study of CagriSema on Muscle Health in Adults with Obesity

This study tests a new medication called CagriSema to understand how it affects muscle health while helping people lose weight. You'll be in the trial for about a year, and researchers will monitor your muscle function and body composition.

Aarhus N
NCT07184086Recruiting· Phase 1
Weight loss and metabolism study with two medicines

This study tests how two medicines, cagrilintide and semaglutide, affect your metabolism compared to diet alone. It may help you understand how weight loss changes your body's energy use.

Orlando, Florida

Hear when a new Obesity trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.